Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Bally

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Science (New York, N.Y.)|May 5, 2018
C1q restrains autoimmunity and viral infection by regulating CD8<sup>+</sup> T cell metabolismGuang Sheng Ling, Greg Crawford, Norzawani Buang, et al.
Frontiers in Immunology|June 24, 2024
Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoproteinIsabelle Bally, Guillaume Drumont, Véronique Rossi, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Elife|January 16, 2025
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross-stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Cell Reports. Medicine|March 2, 2022
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infectionGuidenn Sulbaran, Pauline Maisonnasse, Axelle Amen, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Science (New York, N.Y.)|May 5, 2018
C1q restrains autoimmunity and viral infection by regulating CD8<sup>+</sup> T cell metabolismGuang Sheng Ling, Greg Crawford, Norzawani Buang, et al.
Frontiers in Immunology|June 24, 2024
Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoproteinIsabelle Bally, Guillaume Drumont, Véronique Rossi, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Elife|January 16, 2025
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross-stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Cell Reports. Medicine|March 2, 2022
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infectionGuidenn Sulbaran, Pauline Maisonnasse, Axelle Amen, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Pageof 4